Court win for Unit­ed Ther­a­peu­tics will re­strain loom­ing com­pe­ti­tion for its soon-to-be block­buster

Unit­ed Ther­a­peu­tics claimed vic­to­ry ear­li­er this week in a patent bat­tle against Liq­uidia Tech­nolo­gies, which won ten­ta­tive FDA ap­proval for its tre­pros­tinil in­hala­tion pow­der, Yutrepia, to treat pul­monary ar­te­r­i­al hy­per­ten­sion (PAH) and would com­pete di­rect­ly with Unit­ed’s soon-to-be block­buster Ty­va­so DPI.

The Delaware-based dis­trict court found that Liq­uidia failed to prove by “clear and con­vinc­ing ev­i­dence” that cer­tain claims on one of the patents are in­valid. But both com­pa­nies claimed vic­to­ry over oth­er parts of the de­ci­sion, and when Yutrepia will launch is still up in the air.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER